Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28516521 | 1.00 | FOLH1 (0.58) | FOLH1 | |
| SCHEMBL16802279 | 0.98 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL31095116 | 0.93 | FOLH1 (0.60) | FOLH1 | |
| SCHEMBL16800300 | 0.92 | FOLH1 (0.50) | FOLH1 | |
| SCHEMBL31384213 | 0.90 | NOD1 (0.52) | FOLH1 | |
| SCHEMBL25482404 | 0.87 | NOD1 (0.51) | FOLH1 | |
| SCHEMBL16641921 | 0.86 | FOLH1 (0.54) | FOLH1 | |
| SCHEMBL25482477 | 0.86 | NOD1 (0.54) | FOLH1 | |
| SCHEMBL25482680 | 0.86 | NOD1 (0.54) | FOLH1 | |
| SCHEMBL16645390 | 0.86 | FOLH1 (0.62) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3524277-B1 | PSMA-TARGETING COMPOUND AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-3222617-B1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-113149921-A | Homogenic and xenogenic multivalent inhibitors of Prostate Specific Membrane Antigen (PSMA) and uses thereof | 约翰霍普金斯大学 | 2021-07-23 | — | — | CN | disclosed |
| CN-107382890-B | Homogenic and xenogenic multivalent inhibitors of Prostate Specific Membrane Antigen (PSMA) and uses thereof | 约翰霍普金斯大学 | 2021-01-29 | — | — | CN | disclosed |
| US-9884132-B2 | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-9776977-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3222617-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | The Johns Hopkins University (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2408755-B1 | Urea-based peptide compounds useful for detecting inter alia prostate cancer | UNIV JOHNS HOPKINS (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170049912-A1 | HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-23 | — | — | US | disclosed |
| US-9371360-B2 | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-06-21 | — | — | US | disclosed |
| US-9056841-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
| US-20140341804-A1 | HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PMSA) AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-11-20 | — | — | US | disclosed |
| US-20120009121-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049912-A1 | HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF | KLK3, UTS2R, UROD | FOLH1 4/4885 |
| US-20120009121-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | FOLH1 1/4885 |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | FOLH1 1/4885 |
| US-20140341804-A1 | HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PMSA) AND USES THEREOF | PSMA1, KLK3, PSMA2 | FOLH1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.